is sopravivenza totali (overall survival  os) fl  istudji kumbinati sena wara l bidu tal kura kienet ta  82 f pazjenti kkurati b lenalidomide/ dexamethasone kontra 75 f pazjenti kkurati bil plaċebo/ dexamethasone b medjan ta  tul ta  żmien tal follow up ta  98 0 ġimgħa (minimu